Licensing · Latin America · Announced 1 Jul 2026
Dongkook Pharmaceutical → Faes Farma
Faes Farma signed an exclusive licence and supply agreement with Dongkook Pharmaceutical for Uresco in 13 Latin American countries, with payments of up to €2 million plus a share of sales over ten years from launch.
Parties: Dongkook Pharmaceutical (South Korea) → Faes Farma (Spain)
- Deal type
- Licensing
- Value
- See terms
- Territory
- 13 Latin American countries (not listed)
- Therapeutic area
- Other
- Asset
- Uresco
- Announced
- 1 Jul 2026
Our analysis
Why this matters
Faes Farma announced on 1 July 2026 an exclusive licence and supply agreement with Dongkook Pharmaceutical for Uresco in 13 Latin American countries. The deal provides for payments of up to €2 million plus payments linked to a percentage of sales, and runs for ten years from commercial launch. Regulatory filings in Latin America are to begin; no dates were given. The brief does not name the product's active ingredient, indication or the 13 countries.
For BD directors at Asian originators, the deal shows Latin America being reached through a European company with an established regional network rather than local distributors one by one.
The full analysis is free to read with a work email on this page.
Source: Reuters brief (via GBM)